<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481610</url>
  </required_header>
  <id_info>
    <org_study_id>PEMEX-805415-00-2</org_study_id>
    <nct_id>NCT01481610</nct_id>
  </id_info>
  <brief_title>Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia</brief_title>
  <official_title>Comparison of the Effects on Renal Function of Lumiracoxib and Diclofenac in Patients With Chronic Kidney Failure K/DOQI Stage III at the HCSAE PEMEX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Central Sur de Pemex</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Central Sur de Pemex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of lumiracoxib in this particular
      population is associated with a decrease in glomerular filtration rate (GFR) compared to
      diclofenac; and to compare the magnitude of such impairment, if any, associated with use of
      lumiracoxib and diclofenac.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis shows harma to one of the study arms.
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GFR</measure>
    <time_frame>Change in GFR will be measured at start of treatment (baseline) and again at the end of treatment (max. 10 days) for each patient</time_frame>
    <description>Magnitude of change in GFR (ml / min) as measured by creatinine clearance in urine over 24 hours, considering the initial and final value at the end of the study. Creatinine clearance will be measured twice: initially, prior to the first dose of medication (baseline), and again at the end of treatment (ie. 10 days after starting dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>Use of rescue medication will be assessed at the end of treatment (ie. 10 days after first dose)</time_frame>
    <description>Proportion of patients in each group who required rescue analgesic drugs at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective improvement in pain</measure>
    <time_frame>Pain will be assessed with VAS at the start of treatment and again at the end of treatment (ie. 10 days after first dose)</time_frame>
    <description>Change in the subjective perception of pain, assessed with help of a validated Visual Analog Scale both prior to the start of treatment and again at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Arthralgia</condition>
  <arm_group>
    <arm_group_label>Lumiracoxib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumiracoxib</intervention_name>
    <description>Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.</description>
    <arm_group_label>Lumiracoxib group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.</description>
    <arm_group_label>Diclofenac group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic joint pain, requiring analgesia

          -  pre-existing chronic kidney injury, stage K/DOQI III (GFR 30 - 59 ml/min)

          -  in a stable phase of CKD (i.e. not AKI, not hospitalized)

          -  without contraindications for NSAID therapy

          -  who have signed an informed consent

        Exclusion Criteria:

          -  having received any NSAID 2 weeks prior to study start

          -  history of / actual PUD

          -  patients with ESRD (K/DOQI IV, V or replacement therapy)

          -  history of hypersensitivity or allergies to any of the treatments

          -  history of / actual GI bleeding

          -  with impaired liver function tests

          -  using ACEI / ARB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Molina-Calzada, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Petroleos Mexicanos - Servicios de Salud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Arce-Salinas, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Petroleos Mexicanos - Servicios de Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Central Sur de Alta Especialidad PEMEX</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>14140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Central Sur de Pemex</investigator_affiliation>
    <investigator_full_name>Carlos Molina-Calzada</investigator_full_name>
    <investigator_title>Resident - Internal Medicine Department</investigator_title>
  </responsible_party>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Arthralgia</keyword>
  <keyword>NSAID</keyword>
  <keyword>Diclofenac</keyword>
  <keyword>Lumiracoxib</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Lumiracoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

